Publication & Citation Trends
Publications
0 total
study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after
Cited by 0
Semantic Scholar
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
Cited by 240
Semantic Scholar
CGO: utilizing and integrating gene expression microarray data in clinical research and data management OA
Cited by 12
Semantic Scholar
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. OA
Cited by 555
Semantic Scholar
Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571)) OA
Cited by 32
Semantic Scholar
Antitumor activity of thalidomide in refractory multiple myeloma. OA
Cited by 2,592
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(4)
Cancer Treatment and Pharmacology
(3)
Protein Degradation and Inhibitors
(2)
Venous Thromboembolism Diagnosis and Management
(1)
Gene expression and cancer classification
(1)
Affiliations
Bristol-Myers Squibb (Switzerland)
University of Arkansas for Medical Sciences